Clinical Trial Update: Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing non-extended versus 24-week extended Peg-Intron (pegylated interferon alfa-2b) with ribavirin in genotype 1 chronic hepatitis C after 24…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2011-03-24